{"id":51870,"date":"2022-12-12T18:02:22","date_gmt":"2022-12-12T17:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/orca-bio-presents-encouraging-interim-clinical-data-on-orca-q-in-haploidentical-allogeneic-hematopoietic-stem-cell-transplants-at-64th-ash-annual-meeting\/"},"modified":"2022-12-12T18:02:22","modified_gmt":"2022-12-12T17:02:22","slug":"orca-bio-presents-encouraging-interim-clinical-data-on-orca-q-in-haploidentical-allogeneic-hematopoietic-stem-cell-transplants-at-64th-ash-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/orca-bio-presents-encouraging-interim-clinical-data-on-orca-q-in-haploidentical-allogeneic-hematopoietic-stem-cell-transplants-at-64th-ash-annual-meeting\/","title":{"rendered":"Orca Bio Presents Encouraging Interim Clinical Data on Orca-Q in Haploidentical Allogeneic Hematopoietic Stem Cell Transplants at 64th ASH Annual Meeting"},"content":{"rendered":"
\n

\n\u2013 Orca-Q is Orca Bio\u2019s investigational high-precision cell therapy designed to overcome the challenges of haploidentical allogeneic hematopoietic stem cell transplant (alloHSCT) \u2013<\/i>\n<\/p>\n

\n\u2013 <\/b>Interim multi-center Phase 1 clinical trial results show that Orca-Q improved graft-versus-host disease-free, relapse-free survival in haploidentical alloHSCT compared to standard of care, without use of post-transplant cyclophosphamide \u2013<\/i>\n<\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that interim clinical data from its Phase 1 multi-center trial of its second investigational cell therapy, Orca-Q, were unveiled in an oral presentation at the 64th<\/sup> American Society of Hematology (ASH) Annual Meeting.\n<\/p>\n

<\/a><\/p>\n

\nThe data from the ongoing clinical trial show that Orca-Q reduced the incidence and severity of graft versus host disease (GvHD) and improved graft-versus-host disease-free, relapse-free survival (GRFS) rates in 26 patients matched to haploidentical allogeneic hematopoietic stem cell donors. Unlike standard of care haploidentical allogeneic hematopoietic stem transplant (alloHSCT), Orca-Q does not require post-transplant cyclophosphamide (PTCy).\n<\/p>\n

\n\u201cPatients and transplant physicians are in urgent need of a novel treatment option that improves the chances of survival and the quality of that survival. This is the key limitation of haploidentical transplant, which is currently the only treatment option for the vast majority of blood cancer patients in need of a transplant,\u201d said Amandeep Salhotra, M.D., associate professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. \u201cThese results suggest Orca-Q\u2019s promise to overcome this serious challenge by offering a novel investigational high-precision cell therapy with the potential to significantly improve patient outcomes and reduce serious transplant-related risks.\u201d\n<\/p>\n

\nOrca-Q is an investigational high-precision cell therapy that is a proprietary composition of enriched CD34+ stem cells combined with specific T cell subsets. The findings presented at ASH are from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and chronic myeloid leukemia (CML) who were matched to haploidentical allogeneic donors, defined as matched across at least 4\/8 but fewer than 7\/8 human leukocyte antigen (HLA) loci. Historical controls from the literature of patients who received standard of care haploidentical alloHSCT with PTCy GvHD prophylaxis were used for comparison purposes1,2,3,4<\/sup>.\n<\/p>\n

\nInterim results from the Phase 1 single-arm, open-label trial showed:\n<\/p>\n